Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study
- 20 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 31 (2), 259-269
- https://doi.org/10.1007/s10067-011-1809-z
Abstract
Hydroxychloroquine sulfate (HCQS) is a popular disease-modifying antirheumatic drug (DMARD) despite modest efficacy and toxicity. Ayurveda (ancient India medicinal system) physicians treat rheumatoid arthritis (RA) with allegedly safer herbal formulations. We report a head-to-head comparison in an exploratory drug trial. The objective is to compare standardized Ayurvedic formulations and HCQS in the treatment of RA. One hundred twenty-one patients with active moderately severe RA (ACR 1988 classified) were randomized into a 24-week investigator-blind, parallel efficacy, three-arm (two Ayurvedic and HCQS) multicenter drug trial study; polyherb (Tinospora cordifolia and Zingiber officinale based) and monoherb (Semecarpus anacardium). Study measures included joint counts (pain/tenderness and swelling), pain visual analogue scale, global disease assessments, and health assessment questionnaire. Oral meloxicam (fixed-dosage schedule) was prescribed to all patients during the initial 16 weeks. Patients on prednisolone could continue a fixed stable dose (P < 0.05) did not show significant differences by treatment groups. In the polyherb, monoherb, and HCQS arms, 44%, 36%, and 51%, respectively, showed ACR 20 index improvement. Several efficacy measures improved significantly in the HCQS and polyherb groups with no difference between the groups (corrected P). However, the latter was individually superior to monoherb. Only mild adverse events (gut and skin, and none withdrew) were reported with no differences between the groups. Forty-two patients dropped out. This preliminary drug trial controlled for HCQS demonstrated a standardized Ayurvedic polyherb drug to be effective and safe in controlling active RA. A better-designed study with a longer evaluation period is recommended.This publication has 34 references indexed in Scilit:
- A Randomized Controlled Exploratory Evaluation of Standardized Ayurvedic Formulations in Symptomatic Osteoarthritis Knees: A Government of India NMITLI ProjectEvidence-Based Complementary and Alternative Medicine, 2010
- Research methodological issues in evaluating herbal interventionsOpen Access Journal of Clinical Trials, 2010
- Diet, Ayurveda and interface with biomedicineJournal of Ayurveda and Integrative Medicine, 2010
- Ayurveda-modern medicine interface: A critical appraisal of studies of Ayurvedic medicines to treat osteoarthritis and rheumatoid arthritisJournal of Ayurveda and Integrative Medicine, 2010
- Efficacy and safety of Ayurvedic medicines: Recommending equivalence trial design and proposing safety indexInternational Journal of Ayurveda Research, 2010
- Second World Ayurveda Congress (Theme: Ayurveda for the Future)—Inaugural Address: Part IIIEvidence-Based Complementary and Alternative Medicine, 2008
- Second World Ayurveda Congress (Theme: Ayurveda for the Future)—Inaugural Address: Part IEvidence-Based Complementary and Alternative Medicine, 2008
- Chondroprotective Potential of Fruit Extracts ofPhyllanthus emblicain OsteoarthritisEvidence-Based Complementary and Alternative Medicine, 2008
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988